FDA to start review of subcutaneous Entyvio for Crohn’s disease
The FDA is also reviewing a subcutaneous formulation of Takeda’s blockbuster drug for ulcerative colitis.
The FDA is also reviewing a subcutaneous formulation of Takeda’s blockbuster drug for ulcerative colitis.
What's Your Reaction?
